Format

Send to

Choose Destination
Behav Brain Res. 2015 Jan 15;277:99-120. doi: 10.1016/j.bbr.2014.07.016. Epub 2014 Jul 15.

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Author information

1
Department of Psychiatry, University of California San Diego, La Jolla, CA, United States. Electronic address: ahalberstadt@ucsd.edu.

Abstract

Serotonergic hallucinogens, such as (+)-lysergic acid diethylamide, psilocybin, and mescaline, are somewhat enigmatic substances. Although these drugs are derived from multiple chemical families, they all produce remarkably similar effects in animals and humans, and they show cross-tolerance. This article reviews the evidence demonstrating the serotonin 5-HT2A receptor is the primary site of hallucinogen action. The 5-HT2A receptor is responsible for mediating the effects of hallucinogens in human subjects, as well as in animal behavioral paradigms such as drug discrimination, head twitch response, prepulse inhibition of startle, exploratory behavior, and interval timing. Many recent clinical trials have yielded important new findings regarding the psychopharmacology of these substances. Furthermore, the use of modern imaging and electrophysiological techniques is beginning to help unravel how hallucinogens work in the brain. Evidence is also emerging that hallucinogens may possess therapeutic efficacy.

KEYWORDS:

5-HT2A receptor; Head twitch; Prefrontal cortex; Psychedelic; Visual effects

PMID:
25036425
PMCID:
PMC4642895
DOI:
10.1016/j.bbr.2014.07.016
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center